Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy of Tofacitinib for the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis in Patient Subgroups from Two Randomised Phase 3 Trials.
Menter MA, Papp KA, Cather J, Leonardi C, Pariser DM, Krueger JG, Wohlrab J, Amaya-Guerra M, Kaszuba A, Nadashkevich O, Tsai TF, Gupta P, Tan H, Valdez H, Mallbris L, Tatulych S. Menter MA, et al. Among authors: nadashkevich o. J Drugs Dermatol. 2016 May 1;15(5):568-80. J Drugs Dermatol. 2016. PMID: 27168266 Clinical Trial.
Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial.
van der Heijde D, Baraliakos X, Gensler LS, Maksymowych WP, Tseluyko V, Nadashkevich O, Abi-Saab W, Tasset C, Meuleners L, Besuyen R, Hendrikx T, Mozaffarian N, Liu K, Greer JM, Deodhar A, Landewé R. van der Heijde D, et al. Among authors: nadashkevich o. Lancet. 2018 Dec 1;392(10162):2378-2387. doi: 10.1016/S0140-6736(18)32463-2. Epub 2018 Oct 22. Lancet. 2018. PMID: 30360970 Clinical Trial.
Patients with rheumatoid arthritis facing sick leave or work disability meet varying regulations: a study among rheumatologists and patients from 44 European countries.
Putrik P, Ramiro S, Guillemin F, Péntek M, Sivera F, Sokka T, de Wit M, Woolf AD, Zink A, Andersone D, Berghea F, Butrimiene I, Brouwer S, Cassar K, Charalambous P, Caporali R, Deseatnicova E, Damjanov NS, Finckh A, FitzGerald O, Gröndal G, Gobejishjvili N, Gluszko P, Hirsch M, Jovanovic I, Vencovský J, Janssens X, Keszei AP, Kovarova M, Kull M, Cunha Miranda L, Mayer M, Misevska-Percinkova S, Inanc N, Nadashkevich O, Petersson IF, Puolakka K, Rojkovich B, Radner H, Szabados F, Slobodin G, Shirinsky I, Soroka N, Sidiropoulos P, Shumnalieva R, Sokolovic S, Shukurova S, Tafaj A, Tomšič M, Uhlig T, Verstappen SMM, Boonen A. Putrik P, et al. Among authors: nadashkevich o. Ann Rheum Dis. 2019 Nov;78(11):1472-1479. doi: 10.1136/annrheumdis-2019-215294. Epub 2019 Aug 19. Ann Rheum Dis. 2019. PMID: 31427438
Reporting items for capillaroscopy in clinical research on musculoskeletal diseases: a systematic review and international Delphi consensus.
Ingegnoli F, Herrick AL, Schioppo T, Bartoli F, Ughi N, Pauling JD, Sulli A, Cutolo M, Smith V; European League against Rheumatism (EULAR) study group on microcirculation in rheumatic diseases and the Scleroderma Clinical Trials Consortium. Ingegnoli F, et al. Rheumatology (Oxford). 2021 Mar 2;60(3):1410-1418. doi: 10.1093/rheumatology/keaa457. Rheumatology (Oxford). 2021. PMID: 32984894
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials.
Papp KA, Menter MA, Abe M, Elewski B, Feldman SR, Gottlieb AB, Langley R, Luger T, Thaci D, Buonanno M, Gupta P, Proulx J, Lan S, Wolk R; OPT Pivotal 1 and OPT Pivotal 2 investigators. Papp KA, et al. Br J Dermatol. 2015 Oct;173(4):949-61. doi: 10.1111/bjd.14018. Br J Dermatol. 2015. PMID: 26149717 Clinical Trial.
Reconciling healthcare professional and patient perspectives in the development of disease activity and response criteria in connective tissue disease-related interstitial lung diseases.
Saketkoo LA, Mittoo S, Frankel S, LeSage D, Sarver C, Phillips K, Strand V, Matteson EL; OMERACT Connective Tissue Disease–Interstitial Lung Diseases Working Group; OMERACT Connective Tissue Disease-Interstitial Lung Diseases Working Group. Saketkoo LA, et al. J Rheumatol. 2014 Apr;41(4):792-8. doi: 10.3899/jrheum.131251. Epub 2014 Feb 1. J Rheumatol. 2014. PMID: 24488412 Free PMC article. Review.
Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials.
Saketkoo LA, Mittoo S, Huscher D, Khanna D, Dellaripa PF, Distler O, Flaherty KR, Frankel S, Oddis CV, Denton CP, Fischer A, Kowal-Bielecka OM, LeSage D, Merkel PA, Phillips K, Pittrow D, Swigris J, Antoniou K, Baughman RP, Castelino FV, Christmann RB, Christopher-Stine L, Collard HR, Cottin V, Danoff S, Highland KB, Hummers L, Shah AA, Kim DS, Lynch DA, Miller FW, Proudman SM, Richeldi L, Ryu JH, Sandorfi N, Sarver C, Wells AU, Strand V, Matteson EL, Brown KK, Seibold JR; CTD-ILD Special Interest Group. Saketkoo LA, et al. Thorax. 2014 May;69(5):428-36. doi: 10.1136/thoraxjnl-2013-204202. Epub 2013 Dec 24. Thorax. 2014. PMID: 24368713 Free PMC article.
The development of systemic sclerosis classification criteria.
Walker JG, Pope J, Baron M, Leclercq S, Hudson M, Taillefer S, Edworthy SM, Nadashkevich O, Fritzler MJ. Walker JG, et al. Among authors: nadashkevich o. Clin Rheumatol. 2007 Sep;26(9):1401-9. doi: 10.1007/s10067-007-0537-x. Epub 2007 Feb 7. Clin Rheumatol. 2007. PMID: 17285223 Review.
14 results